FDA Approval Of Xarelto Bodes Well For Drug’s Future Expansion

The July 1 approval of Johnson & Johnson’s novel anticoagulant Xarelto for prevention of deep vein thrombosis is an important step for J&J and its ex-U.S. partner Bayer AG as they gear up to play in the highly promising but increasingly complicated world of novel anticoagulants.